Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice.

ABSTRACT:

Background

Cervical cancer ranks as the fourth most common cancer affecting women globally, with HPV as the primary etiology agent. Prophylactic HPV vaccines have substantially reduced the incidence of cervical cancer.

Methods

This study assessed the immunogenicity of SCT1000, a 14-valent recombinant virus-like particle (VLP) vaccine developed by Sinocelltech, Ltd. using pseudovirion-based neutralization assays (PBNAs) and total IgG Luminex immunoassays (LIAs). Currently in phase III clinical trials in China, SCT1000 targets the same HPV types as Gardasil 9^®, plus five additional high-risk types, thereby covering twelve high-risk HPV types implicated in 96.4% of cervical cancer cases.

Results

In murine models, a dose of 1.85 μg per mouse was identified as o

SUBMITTER: Bei L 

PROVIDER: S-EPMC11599024 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature